OptimizeRx named Andy D'Silva chief financial officer, effective Jan. 1, 2027, succeeding Ed Stelmakh.
D'Silva previously served as chief business officer, covering financial strategy, capital allocation, investor relations, corporate development, and long-range planning.
Heather Favazza was appointed chief accounting officer, effective Jan. 1, 2027.
Favazza has served as corporate controller for eight years, overseeing accounting operations, financial reporting, internal controls, and compliance.
Stelmakh will remain chief financial and strategy officer through Dec. 31, 2026, then serve as strategic adviser through the end of 2027.
OPRX•
